2015 Competition FDA Pharmacology 
European Pharmaceutical Review
OCTOBER 19, 2022
2 Recently, the US Patent and Trademark Office (US PTO) reiterated the concern that patents have been “misused to inhibit and delay – for years and even decades – competition from generic drugs and biosimilars, denying Americans access to lower-cost drugs.” Letter to FDA, 06 July 2022. Internet] [link]. Cited 25 September 2022].
pharmaphorum
JANUARY 16, 2023
There were developments in the past 12 months, true – Biogen/Eisai’s lecanemab (now branded Leqembi) showed clear success in the Clarity AD trial and received approval by FDA on 6th January 2023. And all are predominantly prevented or treated with medicines that are decades old. Innovation will power the market.
Expert insights. Personalized for you.
73 
Let's personalize your content